Skip to main content
Top
Published in: International Cancer Conference Journal 3/2020

01-07-2020 | Prostate Cancer | Case report

Difficulty in distinguishing radiation-induced prostate sarcoma from radiation mucositis in a patient with persistent urinary retention and hematuria after prostate cancer radiotherapy

Authors: Shinya Hiraoka, Toshiyuki Imagumbai, Yasuhiro Kosaka, Kengo Ogura, Takayuki Hattori, Takashi Ogata, Daisuke Yamashita, Mutsushi Kawakita, Masaki Kokubo

Published in: International Cancer Conference Journal | Issue 3/2020

Login to get access

Abstract

Urinary retention and hematuria owing to radiation-induced mucositis are occasional late adverse events in patients with prostate cancer. Moreover, radiation-induced secondary malignancies are late adverse events, although they are extremely rare. Herein, we describe a case of radiation-induced secondary malignancy of the prostate that was initially difficult to distinguish from radiation mucositis. A 74-year-old man with prostate cancer underwent brachytherapy and external beam radiotherapy 9 years ago. Twenty-eight months after irradiation, he presented with urinary retention and hematuria owing to radiation mucositis and underwent transurethral resection of the prostate. At 89 months after irradiation, the patient again showed urinary retention and hematuria. The cause of urinary retention and hematuria could not be identified on cystoscopy. Despite receiving medications, the patient’s symptoms did not improve. Therefore, transurethral fulguration was performed, and prostate biopsy revealed spindle cell sarcoma. A diagnosis of radiation-induced undifferentiated pleomorphic/spindle cell sarcoma was made, and the patient underwent total cystectomy and construction of the ileal conduit. Two weeks after the surgery, computed tomography revealed peritoneal dissemination. The patient died 5 weeks after the surgery. The case findings indicate that clinicians should consider the possibility of radiation-induced secondary malignancy; moreover, thorough pathological examination of the prostate with CT and MRI is important to distinguish RISM from radiation mucositis even if no tumors are found on cystoscopy.
Literature
1.
go back to reference Thariat J, Italiano A, Collin F et al (2012) Not all sarcomas developed in irradiated tissue are necessarily radiation-induced-spectrum of disease and treatment characteristics. Crit Rev Oncol Hematol 83:393–406CrossRef Thariat J, Italiano A, Collin F et al (2012) Not all sarcomas developed in irradiated tissue are necessarily radiation-induced-spectrum of disease and treatment characteristics. Crit Rev Oncol Hematol 83:393–406CrossRef
2.
go back to reference Fatiha EI, Robert B (2009) A review of human carcinogens—part D: radiation. Lancet Oncol 10(8):751–752CrossRef Fatiha EI, Robert B (2009) A review of human carcinogens—part D: radiation. Lancet Oncol 10(8):751–752CrossRef
3.
go back to reference May AW, Isildinha M, Kara H (2008) Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 72(1):58–68CrossRef May AW, Isildinha M, Kara H (2008) Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 72(1):58–68CrossRef
4.
go back to reference Christopher JD, Alyson L, Robert K et al (2016) Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 352:i851 Christopher JD, Alyson L, Robert K et al (2016) Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 352:i851
5.
go back to reference Wang X, Liu L, Tang H et al (2013) Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. Urology 82:160–165CrossRef Wang X, Liu L, Tang H et al (2013) Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. Urology 82:160–165CrossRef
6.
go back to reference Brenner DJ, Curtis RE, Hall EJ et al (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:398–406CrossRef Brenner DJ, Curtis RE, Hall EJ et al (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:398–406CrossRef
7.
go back to reference Bjerkehagen B, Smeland S, Walberg L et al (2008) Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol 47:1475–1482CrossRef Bjerkehagen B, Smeland S, Walberg L et al (2008) Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol 47:1475–1482CrossRef
9.
go back to reference Domínguez A, Piulats JM, Suárez JF et al (2013) Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer. Acta Oncol 52:1215–1216CrossRef Domínguez A, Piulats JM, Suárez JF et al (2013) Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer. Acta Oncol 52:1215–1216CrossRef
10.
go back to reference Roach M, Hanks GM, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974CrossRef Roach M, Hanks GM, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974CrossRef
Metadata
Title
Difficulty in distinguishing radiation-induced prostate sarcoma from radiation mucositis in a patient with persistent urinary retention and hematuria after prostate cancer radiotherapy
Authors
Shinya Hiraoka
Toshiyuki Imagumbai
Yasuhiro Kosaka
Kengo Ogura
Takayuki Hattori
Takashi Ogata
Daisuke Yamashita
Mutsushi Kawakita
Masaki Kokubo
Publication date
01-07-2020

Other articles of this Issue 3/2020

International Cancer Conference Journal 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine